In vitro release of therapeutically active ingredients from polymer matrixes

An in-vitro evaluation of silicone elastomer latex for topical drug delivery

A silicone elastomer latex was evaluated as a topical drug-delivery system. With the addition of a fumed silica and the removal of water, the latex produced elastomeric solid films. The water vapour permeability of the solid film was found to be a function of the film composition. An increase in silica content and the incorporation of a water-soluble component, PEG 3350, rendered the silicone elastomer-free film even more permeable to water vapour. The release of hydrocortisone from the elastomer film can be described by a matrix-diffusion-controlled mechanism. Drug diffusion is thought to occur through the hydrophobic silicone polymer network and the hydrated hydrophilic silica region in the film matrix. Silicone elastomer film with a higher silica content exhibited a faster drug-release rate. The addition of PEG 3350 to the film further enhanced the drug-release rate.

Effect of drug-vinyl copolymer delivery composites on the rat prostate

A radiation polymerized drug-vinyl copolymer delivery composite (0.8 mm in diameter, 3 mm long) was inserted into the right-lobe ventral prostate (I), into the right testis (II), and subcutaneously (III) into the back of male Wistar rats. The implantation was carried out over a period of 12 weeks maximum. From the relationship between the site of surgical insertion of the implant and the physiologic response (as measured by the decrease in the weight of the prostatic organs, e.g., ventral prostates, dorsolateral prostates, and seminal vesicles), it was found that in an AA560-containing composite (36 micrograms daily), the physiologic response is increased in order of (III) greater than (II) greater than (I). The same tendency was observed in the Estracyt-containing composite system (15 micrograms daily). The difference in the physiologic response owing to the site of surgical insertion of the implant was not observed in an E2-17 beta-containing composite (6 micrograms daily), although this composite showed the strongest physiologic response. No physiologic response in rats with CMA-containing composite (28 micrograms daily) was noted.

In vivo release of testosterone from vinyl polymer composites prepared by radiation-induced polymerization

Polymer-testosterone composites with long periods of controlled slow release were made by radiation-induced polymerization in a supercooled state at low temperature using glass-forming monomers. The in vitro release of testosterone from various vinyl polymer composites was found to follow a matrix-controlled process (Q-t1/2). The rate of drug delivery was accelerated with increasing water content of polymers. In experiments in vivo, the composites were implanted subcutaneously in the back of castrated rats during the 30 day test period. The in vivo release rate of testosterone was a little smaller than in vitro. This difference between two releases also increased with the increase of hydrophilicity of polymer. The physiological response in rats was investigated by measuring the weight of ventral prostate and serum testosterone concentration with testosterone-containing composites. The weight of ventral prostate increased linearly with increasing rate of drug release and the serum testosterone concentration could be correlated with the release and with the weight increase of ventral prostate. It was found from microscopic observation that the used polymer carriers had relatively good biocompatibility to cause little foreign body reaction.